The cost-effectiveness of pembrolizumab combined with chemotherapy versus platinum-based doublet chemotherapy for the first-line treatment of patients with metastatic nonsquamous NSCLC without EGFR or ALK mutations was reported in six studies. This evidence concerns the gene ALK and non-small cell lung carcinoma.